Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm talratamab monotherapy study in relapsed small cell lung cancer with mild interstitial pneumonia
jRCT1031250750Phase 2Recruiting
- Sponsor
- Government research grant (planned application)
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talquetamab in small cell lung cancer (SCLC), sponsored by Government research grant (planned application). Primary endpoint: 6-month progression-free survival rate. Started Oct 2026; status: recruiting.
02
Drugs
talquetamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT1031250750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250750.